JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis

  • 0Department of Anatomy, University Hospital Essen, Essen, Germany.
Plos One +

|

January 27, 2025

|

January 27, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Prostate cancer progression involves stromal-epithelial interactions affecting xCT and AL122023.1 expression. This study reveals xCT

Area Of Science

  • Oncology
  • Molecular Biology
  • Cancer Research

Background

  • Prostate cancer is a leading global malignancy in males.
  • Stromal-epithelial interactions significantly influence cancer development.
  • Previous research indicated reduced xCT and AL122023.1 expression in LNCaP cells due to stromal interactions.

Purpose Of The Study

  • To validate the repression of xCT and AL122023.1 at RNA and protein levels.
  • To investigate the interaction between lncRNA, miRNAs (miR-26a, miR-30d, miR-30e), and xCT/AL122023.1.
  • To explore the expression pattern of xCT in various prostate tissues and its potential as a therapeutic target.

Main Methods

  • Quantitative real-time PCR for RNA level validation.
  • Western Blotting for protein level validation.
  • Luciferase reporter assays to verify lncRNA-miRNA interactions.
  • Immunostaining to analyze xCT expression in prostate tissues.

Main Results

  • Repression of xCT and AL122023.1 was confirmed at both RNA and protein levels.
  • While specific miRNAs did not directly inhibit xCT protein expression, an indirect inhibitory effect of AL122023.1 on xCT was observed.
  • xCT expression was precisely localized in neuroendocrine cells across fetal, juvenile, adult, benign prostatic hyperplasia, and advanced prostate cancer tissues.

Conclusions

  • Stromal-epithelial interactions modulate xCT and AL122023.1 expression in prostate cancer.
  • The study elucidates a complex regulatory network involving lncRNAs, miRNAs, and target genes.
  • xCT is identified as a potential biomarker or therapeutic target, particularly in high-risk prostate cancer.